ResearcherUniversity of ArizonaActive in the last 2 years

Nicholas Galouzis

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8086-652X; OpenAlex author ID A5096328646. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2026: 2 papers

Papers 2

Chemotherapy dose intensity and outcomes in resected pancreatic cancer. Co-author DOI 10.1016/j.gassur.2025.102287 ↗
Association of Neoadjuvant Therapy on Pathologic and Clinical Outcomes for Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.jss.2025.11.065 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Mohammad R. Khreiss · 2 shared papers, 2026 · strength 0.65
- Paper Chemotherapy dose intensity and outcomes in resected pancreatic cancer. DOI 10.1016/j.gassur.2025.102287 ↗
- Paper Association of Neoadjuvant Therapy on Pathologic and Clinical Outcomes for Pancreatic Adenocarcinoma. DOI 10.1016/j.jss.2025.11.065 ↗
Taylor Sohn Riall · 2 shared papers, 2026 · strength 0.65
- Paper Chemotherapy dose intensity and outcomes in resected pancreatic cancer. DOI 10.1016/j.gassur.2025.102287 ↗
- Paper Association of Neoadjuvant Therapy on Pathologic and Clinical Outcomes for Pancreatic Adenocarcinoma. DOI 10.1016/j.jss.2025.11.065 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.